'Creatine directly causes Cancer Metastasis' - Multiple Studies

Scientific concepts / discoveries / nature phenomena mentioned

Creatine and cancer metastasis (spread of cancer)

• A mechanistic/preclinical line of evidence is discussed suggesting that creatine accelerates cancer progression and metastasis, associated with reduced survival in animal cancer models.
• The presenter describes that when animals are fed creatine and then exposed to cancer (example shown: HCT116):
  • Survival is reduced
  • Cancer spread appears more aggressive

Creatine biosynthesis and a “rate-limiting” enzyme

• The discussion focuses on how tumor and metastatic cells may increase creatine production using a synthesis step described as rate-limiting in creatine production: GATM.
• Key observations described:
  • Metastatic cancer cells show higher GATM expression/activity than cells in the primary tumor environment.
  • A similar pattern is reported in humans: higher expression of the creatine synthesis enzyme in metastatic human cancer is associated with worse survival outcomes.

Important measurement distinctions / uncertainties

• The presenter notes that some evidence is not direct measurement of creatine supplementation:
  • Enzyme expression in tumors/metastases does not prove what happens when someone ingests creatine.
  • Some human results reflect molecular expression or single blood measurements, rather than controlled supplementation.

Associational human evidence using blood creatine

• A study using NMR (nuclear magnetic resonance) spectroscopy is described to quantify molecules in blood.
• Reported association:
  • Higher blood creatine levels in women are associated with an increased risk of breast cancer (reported as up to ~84% increased risk).
• Limitations highlighted:
  • Blood was measured only at baseline, while cancer was measured over ~13 years later.
  • NMR peaks may include overlapping signals, meaning creatine cannot be perfectly separated from related molecules (e.g., creatine vs creatinine and lysine share/overlap at a peak).

Creatine consumption vs cancer risk (food-derived creatine)

• Another study is described as investigating creatine consumption (primarily from meat/food), rather than supplementation.
• Reported finding:
  • Creatine consumption associates with reduced risk of cancer.
• Limitations highlighted:
  • Estimated intake
  • Retrospective design
  • Creatine measured/estimated only once
  • A potential conflict of interest is mentioned: one author is on a scientific advisory board for a creatine company and holds a patent related to liquid creatine.

Randomized controlled trial (supplementation in malignant cancer patients)

• A randomized controlled trial is summarized in which patients with confirmed malignant cancer receive creatine supplementation.
• Reported outcomes:
  • Creatine did not help against cancer-induced weight loss
  • A survival analysis is presented showing no separation between creatine and placebo groups, interpreted as evidence creatine did not increase cancer-related death risk
• Limitations highlighted:
  • The primary outcome was weight, not survival (survival effects may be underpowered).
  • Dosage/timing described: ~20 g/day for 5 days, then ~2 g/day, with supplementation for about 2 months while survival was tracked longer.

Proposed mechanism terms (named but not deeply detailed in subtitles)

• The presenter references mechanisms involving SMAD2/3, MPS1, and E-cadherin, described as pathways that are “believed to be implicated” in cancer progression/metastasis.

---

Methodologies / study designs outlined

• Animal experiments (preclinical models)

  • Feed animals creatine vs control
  • Apply a cancer model (example shown: HCT116)
  • Measure:
    • Survival over time
    • Metastatic spread
  • Sample creatine-related factors from:
    • Primary tumor region
    • Metastatic regions

• Human observational study using NMR

  • Use NMR spectroscopy on blood to quantify molecules/peak patterns
  • Relate baseline blood molecule levels to later cancer incidence (example: breast cancer)
  • Limitation: blood measured once; peak overlap can prevent perfect isolation of creatine

• Retrospective human intake study

  • Estimate food-based creatine consumption (e.g., meat intake)
  • Compare risk of overall cancer occurrence
  • Limitation: retrospective, estimated intake, and single timepoint measurement/estimation

• Randomized controlled trial in malignant cancer

  • Randomly assign cancer patients to creatine supplementation vs placebo
  • Primary outcome: weight loss (not survival)
  • Secondary/graph outcome: survival analysis

---

Researchers / sources featured (as stated in subtitles)

• HCT116 (presented as the cancer cell/tumor model; not a person)
• GATM (enzyme name; not a person)

No individual researchers (by name) or journal/source titles are explicitly provided in the subtitles.